MyFinsight
Home
Blog
About
Net increase
(decrease) in cash and cash...
-$18,366,803
(-186.42%↓ Y/Y)
Stock-based compensation
expense
$5,346,010
(-14.48%↓ Y/Y)
Accrued expenses and
other current...
$5,143,652
(1892.46%↑ Y/Y)
Prepaid expenses and
other current assets
-$358,875
(-4668.47%↓ Y/Y)
Maturities of investments -
marketable securities
$49,125,000
(56.70%↑ Y/Y)
something is missing
$385,062
Net cash used in
operating activities
-$12,443,612
(-28.58%↓ Y/Y)
Net cash provided by
(used in) investing...
-$5,908,702
(-119.12%↓ Y/Y)
Net cash provided by
financing activities
-$14,489
(-145.60%↓ Y/Y)
Canceled cashflow
$10,848,537
Canceled cashflow
$49,125,000
Canceled cashflow
$385,062
Net loss
-$19,591,231
(16.97%↑ Y/Y)
Purchases of investments -
marketable securities
$55,033,702
Deferred offering costs
$399,551
Prepaid research and
development
$1,831,731
(3083.02%↑ Y/Y)
Non-cash accretion on
marketable securities
$1,154,664
Accounts payable
-$625,585
(-139.28%↓ Y/Y)
Other assets
$88,938
Back
Back
Cash Flow
Inhibikase Therapeutics, Inc. (IKT)
Inhibikase Therapeutics, Inc. (IKT)
source: myfinsight.com